Oncocidia Ltd.
Pharmaceutical Manufacturing
Amersham, Buckinghamshire 116 followers
A novel radiopharmaceutical anti-cancer agent
About us
The Company is developing a targeted radiopharmaceutical cancer treatment called Oncocidia. The treatment is based on a novel small-molecule compound 131I-Hyp (hypericin labelled with Iodine-131), which targets and destroys partially necrosed tumors. Oncocidia is indication agnostic and can be applied to a wide range of solid tumors. It is particularly suited to use as an adjuvant to existing treatments where necrosis is created. Extensive programs of in vitro and in vivo pre-clinical research have been undertaken and published, and a clinical standard formulation of the compound has been developed. A Phase I clinical trial is in planning, for launch in early 2020. Market authorization for selected indications is targeted for 2024.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 2-10 employees
- Headquarters
- Amersham, Buckinghamshire
- Type
- Privately Held
- Founded
- 2016
- Specialties
- Oncology and Radiotherapeutics
Locations
-
Primary
Get directions
Anglo House, Bell Lane
Amersham, Buckinghamshire HP6 6FA, GB